Cargando…
In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer
Docetaxel chemotherapy in metastatic prostate cancer offers only a modest survival benefit because of emerging resistance. To identify candidate therapeutic gene targets, we applied a murine prostate cancer orthograft model that recapitulates clinical invasive prostate cancer in a genome-wide CRISPR...
Autores principales: | Rushworth, Linda K, Harle, Victoria, Repiscak, Peter, Clark, William, Shaw, Robin, Hall, Holly, Bushell, Martin, Leung, Hing Y, Patel, Rachana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Life Science Alliance LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556750/ https://www.ncbi.nlm.nih.gov/pubmed/33033111 http://dx.doi.org/10.26508/lsa.202000770 |
Ejemplares similares
-
Tceal5 and Tceal7 Function in C2C12 Myogenic Differentiation via Exosomes in Fetal Bovine Serum
por: Sawada, Aika, et al.
Publicado: (2022) -
Transcription Elongation Factor A (SII)-Like (TCEAL) Gene Family Member-TCEAL2: A Novel Prognostic Marker in Pan-Cancer
por: Sun, Yu, et al.
Publicado: (2022) -
Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment
por: Rushworth, Linda K., et al.
Publicado: (2019) -
CRISPR-Cas9-induced gene knockout in zebrafish
por: Medishetti, Raghavender, et al.
Publicado: (2022) -
Tceal7 Regulates Skeletal Muscle Development through Its Interaction with Cdk1
por: Xiong, Zhenzhen, et al.
Publicado: (2023)